MBX Biosciences (MBX) Non-Current Assets (2023 - 2026)

MBX Biosciences has disclosed Non-Current Assets across 4 years of filings, most recently posting $4.2 million for Q1 2026.

• Non-Current Assets for Q1 2026 came in at $4.2 million, up 152.42% year-over-year; the trailing twelve-month figure through Mar 2026 was $12.7 million (up 161.68% YoY), and the FY2025 annual result was $3.6 million, up 188.63% from the prior year.
• Non-Current Assets came in at $4.2 million for Q1 2026 at MBX Biosciences, up from $3.6 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $4.2 million in Q1 2026 to a low of $715000.0 in Q4 2023.
• The 4-year median for Non-Current Assets is $2.0 million (2025), against an average of $2.2 million.
• Across the five-year window, Non-Current Assets soared 74.69% in 2024 and soared 188.63% in 2025, its largest moves.
• MBX Biosciences' Non-Current Assets stood at $715000.0 in 2023, then jumped by 74.69% to $1.2 million in 2024, then jumped by 188.63% to $3.6 million in 2025, then grew by 15.53% to $4.2 million in 2026.
• The last three Non-Current Assets figures came in at $4.2 million (Q1 2026), $3.6 million (Q4 2025), and $2.6 million (Q3 2025), per Business Quant data.